Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
What the ARC indictment means and what SUD operators should do this week
On June 4, 2026, a federal grand jury in the U.S. District Court for the Eastern District of Kentucky indicted Addiction Recovery Care founder and CEO Tim Robinson on one count of wire fraud and two counts of money laundering. SUD operators, especially Medicaid-dominant platforms and PE-backed founders, should treat this as a watershed FWA enforcement moment and pressure-test billing integrity, board governance, and CEO succession before a subpoena lands. Boards that wait will be reacting from behind.
According to the indictment, Robinson owned ARC, a behavioral health and substance abuse treatment provider with residential and outpatient facilities in the Eastern District of Kentucky, where he also served as chief executive officer. The conduct alleged is not Medicaid billing fraud. The new indictment does not directly relate to the company’s alleged fraudulent billing of Medicaid. Instead, the indictment alleges Robinson devised a scheme to sell ARC’s same federal tax credit payments, worth millions of dollars, to two different companies.
The wire fraud count alone carries serious exposure. If convicted, Robinson faces up to 20 years in prison, a fine of $250,000 or twice the gross gain or loss, whichever is greater, and 3 years of supervised release. The Medicaid story is the bigger systemic warning. The Louisa-based company, which bills the federal Medicaid program for most of its services, also is the subject of an ongoing FBI investigation into possible health care fraud. Federal scrutiny of dominant Medicaid SUD platforms is no longer theoretical. It is happening now, in real time, and the operator-side response cannot be a press release.
Why federal scrutiny lands on dominant Medicaid SUD operators
Data outliers attract enforcement. Federal investigators look for billing patterns that do not look like anybody else’s. A new federal database also shows ARC was paid $70 million from Medicaid for this psychoeducation service in 2023 and 2024, which accounted for 20% of all Medicaid payments under that billing code in the entire country for this two-year period. One provider, one code, one fifth of the national spend. That is the kind of signal that puts the HHS Office of Inspector General, the FBI Louisville Field Office, and the EDKY U.S. Attorney’s Office in motion.
The Kentucky picture got even louder. Payments to addiction treatment providers in Kentucky for psychoeducation absolutely exploded in recent years, quadrupling to $34.7 million from 2020 to 2023, and then quadrupling again in 2024 alone to $165.6 million. A separate civil exposure followed. ARC, to attempt to resolve an ongoing federal investigation, has negotiated a proposed settlement with the U.S. Department of Justice to pay the government $27.7 million, $16 million of which is restitution.
Now layer on the macro. Of the more than $6.8 billion in False Claims Act settlements and judgments reported by the Department of Justice this past fiscal year, over $5.7 billion related to matters that involved the health care industry. Whistleblowers are filing at record pace. The 1,297 qui tam suits filed in fiscal year 2025 breaks the prior record set in 2024 of 980 such cases. Shannon Sumner of PYA put it plainly to Medical Economics: “Investigations are increasingly triggered by analytics, so practices get flagged because their data does not look like their peers.”
If your CFO cannot tell the board what percentage of your revenue comes from any single CPT or HCPCS code, you have a problem. If your utilization review team cannot explain why your average length of stay, weekly hour delivery, or step-down rates differ from peers, that is the gap a relator or auditor will fill for you.
A board-level operating playbook for the next 60 days
Boards typically learn about a federal investigation the same week the press does. That is too late to design governance. The HHS-OIG made the board’s role explicit. The new guidance also includes recommendations to conduct annual internal risk assessments, to consider quality of care as a component of the compliance program, and to emphasize the importance of a board’s and executive leadership’s oversight of compliance. Use the OIG General Compliance Program Guidance as the standing reference for what good looks like.
Here is what the AHS team walks boards through when a peer indictment hits the news:
- Emergency CEO succession protocol. Name an interim CEO, a board-designated compliance liaison, and an outside counsel point of contact within 72 hours. Document the authority delegation in writing. Do not let signature authority and bank access drift.
- Independent compliance review. Engage an outside reviewer, not the same firm that drafted your existing policies, to conduct a focused 60-day chart audit and billing claims sample. Sample by payer, by level of care (PHP, IOP, residential, withdrawal management), and by referral source.
- Document hold and data preservation. Issue a written litigation hold covering EMR data, billing logs, attendance records, marketing contracts, and text messages. Confirm your EMR vendor can support a forensic export.
- Leadership attestations. Require the CEO, CFO, CCO, and clinical director to sign quarterly attestations confirming personal review of compliance metrics. OIG emphasizes that CEOs can demonstrate their support for an organization’s commitment to compliance by signing the introduction to, or including a signed endorsement or similar statement in connection with, the organization’s Code of Conduct.
- Compliance officer reporting line. OIG confirms that the Compliance Officer should report either to the chief executive officer (CEO) of the organization with direct access to the board or directly to the board, have equal stature to other senior leaders, and be an advisor to the CEO, the board and senior leaders on compliance risks facing the company. If yours reports to billing, fix it this month.
The Federal Sentencing Guidelines §8B2.1 framework still anchors how prosecutors evaluate whether a program is real or paper. OIG sticks with the seven elements of compliance identified in the U.S. Sentencing Guidelines as the framework for its compliance program recommendations. Your board minutes should reflect that.
CIA-readiness, IRO selection, and the PE sponsor angle
Corporate Integrity Agreements are not punishment. They are the operating system DOJ and HHS-OIG impose when they no longer trust your internal controls. Getting CIA-ready before you need one is the play. That means a written compliance work plan, a functional Independent Review Organization (IRO) bench, a documented claims sampling methodology, and a board compliance committee charter that actually meets.
When selecting an IRO, look for prior CIA engagement experience, behavioral health domain knowledge, statistician credentials for claims sampling, and zero financial entanglement with your billing or EMR vendors. The OIG has made it clear that quality of care considerations should be included in a compliance program to mitigate patient harm and False Claims Act liability. Build clinical chart review into the sampling design, not just billing accuracy.
For PE sponsors, the warning has been delivered. The DOJ signaled in public remarks at the Federal Bar Association’s Qui Tam Conference that the department was committed also to “holding accountable third parties that cause the submission of false claims,” specifically identifying third party investors, including private equity and venture capital firms. Principal Deputy Assistant Attorney General Brian M. Boynton cautioned third parties who may “influence patient care” and “undermine medical judgment” by providing express direction on how a provider should conduct their business or indirectly by setting revenue targets or benchmarks to prioritize reimbursement. If your sponsor’s investment committee is setting EBITDA targets that only pencil if utilization review approves every admission, that is the diligence question.
Specific controls AHS recommends platforms install before a federal cloud forms:
- Concentration analytics: monthly board report on revenue by CPT/HCPCS code, by payer, and by referring marketing channel.
- Medical necessity documentation tied to the ASAM Criteria 4th Edition for SUD admissions and continued stay, with a separate LOCUS workflow for co-occurring mental health.
- Weekly hour reconciliation for PHP (outpatient, ASAM Level 2.5) and IOP before any claim is submitted. We have written about this before. It still happens every week.
- EKRA (18 U.S.C. § 220) review of every marketing, call center, and lead-generation contract. Compensation tied to head count is the single most common red flag.
- Joint Commission or CARF survey readiness as a baseline, not as a sprint. Accreditors and federal investigators ask overlapping questions.
Frequently asked questions
What specific charges did the DOJ bring against ARC CEO Tim Robinson, and what conduct typically underlies wire fraud and money laundering counts in SUD cases?
The indictment charges one count of wire fraud under 18 U.S.C. § 1343 and two counts of money laundering under 18 U.S.C. § 1957. Count 1 is tied to the Nov. 12, 2025 transmission of signed sale agreements to the broker falsely representing the ERCs had not been previously sold. In SUD cases more broadly, wire fraud often pairs with allegations of false claims to Medicaid, falsified attendance, or upcoded services; money laundering counts typically follow the proceeds into operating accounts and asset purchases.
How should our board structure an emergency CEO succession when the founder is under federal indictment?
Within 72 hours: appoint an interim CEO, separate signature and banking authority from the founder, issue a written litigation hold, retain independent outside counsel (not the founder’s longtime firm), and authorize an independent compliance review. Document every step in board minutes. Communicate with payers, accreditors, and state Medicaid before they call you.
What does a credible 60-day compliance overhaul look like for a Medicaid-dominant SUD operator after a peer indictment?
A real overhaul includes a claims sampling audit by payer and level of care, a concentration analysis on top billing codes, an ASAM 4th Edition medical necessity review, a referral-source and marketing contract review against EKRA and the Anti-Kickback Statute, attendance and weekly-hour reconciliation for PHP and IOP, and board-approved corrective action plans with named owners and dates. The OIG GCPG and Federal Sentencing Guidelines §8B2.1 are your benchmarks.
How do we prepare for a possible Corporate Integrity Agreement or independent monitor before DOJ asks?
Stand up a board compliance committee with a written charter. Pre-select two or three IRO candidates with behavioral health and statistical sampling experience. Build a claims sampling methodology you can hand to an IRO on day one. Maintain a compliance work plan with quarterly board reporting. OIG recommends annual internal risk assessments and board-level oversight of compliance, so the artifacts should already exist.
What billing, medical necessity, and referral-source controls most often trigger federal SUD fraud investigations under FCA, AKS, and EKRA?
The patterns we see: revenue concentration in a single high-margin code that exceeds peer norms, attendance documentation that does not support billed weekly hours for PHP or IOP, medical necessity notes that do not match the authorized level of care, marketing or call-center compensation tied to admissions volume, and authorizations that lag actual service delivery. Health care fraud remained a leading source of False Claims Act settlements and judgments. Of the more than $6.8 billion in False Claims Act settlements and judgments reported by the Department of Justice this past fiscal year, over $5.7 billion related to matters that involved the health care industry. The dollars say it all.
References
- WTVQ: Addiction Recovery Care CEO indicted on wire fraud, money laundering charges (EDKY indictment summary)
- WVXU: Kentucky Addiction Recovery Care owner Tim Robinson indicted for fraud scheme
- Louisville Public Media: How Kentucky’s Addiction Recovery Care allegedly committed massive Medicaid fraud
- Kentucky Lantern: Creditor lays claim to ARC’s $8 million loan and proposed $27.7M DOJ settlement
- U.S. Department of Justice: False Claims Act Settlements and Judgments Exceed $6.8B in Fiscal Year 2025
- HHS-OIG: General Compliance Program Guidance (November 2023)
- Medical Economics: False Claims Act recoveries hit a record $6.8 billion in 2025
- Norton Rose Fulbright: DOJ remarks on PE and third-party FCA accountability